Now that geographic atrophy (GA) therapies are available, primary eye care providers must learn how to spot progression from early/intermediate age-related macular degeneration to GA to develop patient-specific follow-up and referral protocols and effectively counsel patients on the functional impact of GA and the benefits and risks of treatments. Dr. Roger A. Goldberg provides an essential course on charting GA progression.
Charting GA Progression: From Early Signs to Treatment Strategies
Media formats available:
Details
Presenters
Target Audience
This certified CE/CME activity is designed for optometrists.
Grantor Statement
This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Recognize and interpret imaging features indicative of progression from early/intermediate AMD to geographic atrophy
- Examine clinical evidence related to GA progression to develop patient-specific follow-up and referral protocols
- Develop patient-centered communication strategies to effectively educate about the impact of AMD and GA progression on functional vision and quality of life
- Analyze clinical trial evidence to counsel patients about the potential risks and benefits of GA treatments and manage expectations associated with the treatment process
Accreditation
Sponsored by
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 130352, is accredited by COPE for continuing education for optometrists. This course is approved for 1 hour of CE.
Course #: 97035-TD
Activity #: 130352COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty
Roger A. Goldberg, MD, MBA
Partner, Bay Area Retina Associates
Walnut Creek, CA
Faculty, CPMC Ophthalmology Residency
San Francisco, CADisclosure of Relevant Financial Relationships
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
Roger A. Goldberg, MD, MBA has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Abbvie, Adverum, Alimera, Annexon, Apellis, Boehringer Ingelheim, Clearside, EyePoint, Genentech, Janssen, Neurotech/LMRI, Ocular Therapeutix, Ophthea, Orasis, StealthBio, Regeneron, and Zeiss. Advisory Board: Emmetrope Ophthalmics. Grant/Research Support: 4DMT, Abbvie, Affamed, Alexion, Annexon, Apellis, Avirmax, Boehringer Ingelheim, Clearside, Cognition, EyePoint, Genentech, Janssen, Neurotech/LMRI, NovoNordisk, Ocular Therapeutix, StealthBio, Regeneron, UnityBio, and Zeiss. Speaker's Bureau: Apellis Pharmaceuticals.
The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis Pharmaceuticals.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
I. Paul Singh, MD
Paul Petrakos, DO, MS
Paul Petrakos, DO, MS
I. Paul Singh, MD
Paul Petrakos, DO, MS
I. Paul Singh, MD
Sarah H. Van Tassel, MD
Justin Schweitzer, OD, FAAO
